8-K current report · filed Nov 5, 2026

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1IOVA overview

Short answer

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 ended September 30, 2026 financial results announced by Iovance Biotherapeutics.

IOVANCE BIOTHERAPEUTICS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 ended September 30, 2026 financial results announced by Iovance Biotherapeutics
  • Update on recent corporate and operating developments included in Exhibit 99.1
  • Investors should review Exhibit 99.1 for the underlying figures and company outlook

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $121.5M, up ~80% YoY, with U.S. Amtagvi revenue ~$102M, confirming accelerating commercial adoption
  • Gross margin ~60%, up from 56% in Q2, while R&D expense declined ~16% sequentially, improving operating leverage
  • Net loss narrowed to $22.3M from $91.3M, but nine-month net loss remained $148.6M
  • Cash position ~$382M, expected to fund operations well into 2029, reducing near-term financing risk
  • mNSCLC data showed 24.6% ORR in 69 patients and 59.1% in a biomarker-selected subgroup, supporting planned 2027 sBLA and pipeline expansion

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other IOVANCE BIOTHERAPEUTICS, INC. 8-K filings

Get the next IOVA 8-K as it lands

Follow IOVA for push alerts, or ask the research agent what this filing means.